A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001).
Saved in:
| Title: | A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001). |
|---|---|
| Authors: | Chen, Hua-Jun1 (AUTHOR), Tu, Hai-Yan1 (AUTHOR), Hu, Yanping2 (AUTHOR), Fan, Yun3 (AUTHOR), Wu, Guowu4 (AUTHOR), Cang, Shundong5 (AUTHOR), Yang, Yi6 (AUTHOR), Yang, Nong7 (AUTHOR), Ma, Rui8 (AUTHOR), Jin, Gaowa9 (AUTHOR), Xu, Ximing10 (AUTHOR), Liu, Anwen11 (AUTHOR), Tang, Shubin12 (AUTHOR), Cheng, Ying13 (AUTHOR), Yu, Yan14 (AUTHOR), Xu, Chong-Rui1 (AUTHOR), Zhou, Qing1 (AUTHOR), Wu, Yi-Long1 (AUTHOR) syylwu@live.cn |
| Source: | Journal of Hematology & Oncology. 1/5/2025, Vol. 18 Issue 1, p1-10. 10p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 17568722 |
|---|---|
| DOI: | 10.1186/s13045-024-01656-0 |
